Nanoconjugate Strategy Integrating Immunogenic Cell Death Induction and Innate Immune Activation for Potent Anti‐Cancer Immunity
A carrier‐free peptide–cyclic dinucleotide (CDN) nanoconjugate (PCN) is developed that co‐activates immunogenic cell death (ICD) in tumors and stimulator of interferon genes (STING) signaling in DCs and broadly reprogrammed the tumor microenvironment toward anti‐tumor immunity.